1-5 of 5
Nadezhda Zozulya, MD, PhD
Close
Sort by
Journal Articles

Providing Hemostasis for Long-Term Central Venous Access Device (LTCVAD) Placement in Patients with Factor VIII (FVIII) Inhibitors

Gennadii M. Galstian, Michail Spirin, MD, Nadezhda Zozulya, MD PhD, Elena Likhachyova, MD PhD, Valeriy G. Savchenko
Journal: Blood
Blood (2017) 130 (Supplement 1): 3671.
https://doi.org/10.1182/blood.V130.Suppl_1.3671.3671
Published: 2017
Journal Articles

Comparison of Different Phenotypes of Bernard-Soulier Syndrome

Maria A. Kumskova, MD, Nadezhda Zozulya, MD PhD, Valentina N. Dvyrnik, MD PhD, Elena Likhachyova, MD PhD, Elena Yakovleva, MD PhD, Valeriy G. Savchenko
Journal: Blood
Blood (2017) 130 (Supplement 1): 4856.
https://doi.org/10.1182/blood.V130.Suppl_1.4856.4856
Published: 2017
Journal Articles

Actual Status of Inhibitor Hemophilia Management in Russia

Nadezhda Zozulya, MD PhD, Tatiana Andreeva, MD PhD, Vladimir Vdovin, Farida Perina, Elena N. Parovichnikova, MD PhD, Valeri Savchenko, MD PhD Prof.
Journal: Blood
Blood (2015) 126 (23): 5579.
https://doi.org/10.1182/blood.V126.23.5579.5579
Published: 2015
Journal Articles

ITI with a VWF-Stabilised FVIII Concentrate in Haemophilia A Patients with Inhibitors and a Poor Prognosis for ITI Success: Progress Report on octanate ® in the Observational ObsITI Study,

Carmen Escuriola-Ettingshausen, MD, Vladimir Vdovin, MD, Nadezhda Zozulya, MD, PhD, Olga Plyushch, Prof, Wolfhart Kreuz, MD, Bruce A. Schwartz, PhD
Journal: Blood
Blood (2011) 118 (21): 3310.
https://doi.org/10.1182/blood.V118.21.3310.3310
Published: 2011
Journal Articles

The Clinical Development of the First Recombinant FVIII From a Human Cell Line.

Sigurd Knaub, PhD, Nadezhda Zozulya, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 4439.
https://doi.org/10.1182/blood.V114.22.4439.4439
Published: 2009